TY  - JOUR
T1  - LEukotriene inhibitor warning
AU  - Kuehn BM
Y1  - 2009/07/22
N1  - 10.1001/jama.2009.1048
JO  - JAMA
SP  - 375
EP  - 375
VL  - 302
IS  - 4
N2  - 
Since 2007, Merck & Co, Inc, the manufacturer of montelukast, voluntarily added tremor, depression, suicidality, and anxiousness to the list on the drug's label of postmarketing adverse events that have been reported in patients taking the drug. Now, the agency wants a stronger caution on the label of montelukast regarding psychiatric adverse events, as well as similar changes to the labels of asthma drugs zafirlukast and zileuton, which have a similar method of action.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.1048
UR  - http://dx.doi.org/10.1001/jama.2009.1048
ER  -